Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial
ConclusionsIn patients aged < 65 years with high HRD score or gBRCAm, weekly paclitaxel plus carboplatin and eribulin plus carboplatin followed by anthracycline resulted in a pCR rate of > 60% and > 40%, respectively, suggesting potential usefulness of patient stratification using HRD; pCR tended to be low in patients with HRD-negative tumors. Neurotoxicity was less frequent with the eribulin-based regimen.Trial registration:The study has been registered with the University Hospital Medical Information Network Clinical Trials Registry (http://www.umin.ac.jp/ctr/index-j.htm) with unique trial number UMIN000023162. The Japan Breast Cancer Research Group trial number is JBCRG-22.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Japan Health | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Peripheral Neuropathy | Study | Xeloda